Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bluetooth

- PMLiVE

Novo Nordisk’s Xultophy debuts in Switzerland

It is the first market for combination of diabetes treatments Tresiba and Victoza

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

Lilly names head of corporate business development

Promotion for Darren Carroll

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

Eli Lilly HQ

Lilly signs $570m deal for next-gen Humalog

Licenses improved version of its insulin blockbuster from Adocia

Pfizer taps mobile app for patient recruitment

Looks to use smartphone technology to identify rare disease patients

Eli Lilly HQ

Lilly reports first pivotal data for Xeljanz rival in arthritis

Baricitinib on course for regulatory filing in late 2015

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links